Objective: F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) is now a procedure of proven clinical value in the staging of primary lung cancer. This study evaluated the role of PET in the preoperative assessment of resectable lung metastases.
T he surgical treatment of isolated pulmonary metastases has become a widely accepted procedure, with low morbidity and mortality. 1, 2 The oncologic criteria for selection of surgical candidates and the main factors affecting prognosis were investigated in large series of cases. 3, 4 Nonetheless, only 30% of patients with isolated and anatomically resectable lung metastases can be cured by surgery, and there is a need to improve the preoperative selection for optimal candidates.
The value of positron emission tomography (PET) in preoperative staging has been clearly demonstrated for primary lung cancer, [5] [6] [7] [8] where PET assessment of mediastinal and extrathoracic occult metastasis avoids unnecessary surgery in about 10% of patients. Presence of extrathoracic disease in patients with lung metastasis including primary site relapse represents, with rare exceptions, the main reason for exclusion from surgical treatment. Recently, mediastinal lymph node staging has been suggested as another important prognostic factor in otherwise resectable lung metastases. 3, 9, 10 In this view, accurate staging of both extrathoracic deposits and mediastinal nodes becomes essential to improve selection of surgical candidates.
Preoperative PET can modify the clinical management of patients with lung metastasis by detecting occult metastases in other organs, primary site recurrence, nodal spread at the hilar or mediastinal level, as well as by differentiating malignant from benign pulmonary nodules. PET can also help to exclude distant metastases in patients with equivocal evidence at computed tomography (CT) scan or ultrasound. The aim of this study was to evaluate the clinical value of F-18 fluorodeoxyglucose (FDG) PET in addition to spiral CT for preoperative staging of lung metastasis.
Patients and Methods

Patients
Patients with previously treated malignancy and proven or suspected lung metastases deemed resectable at CT scan were evaluated with FDG-PET. A total of 86 patients were studied with 89 PET procedures between August 1998 and December 2000. There were 48 men and 38 women with a mean age of 60 years. Median disease-free survival was 24 months. Primary tumor site of all patients is presented in Table 1 . Thirty patients (35%) had previously submitted to lung metastasectomy and presented recurrent lung metastasis. All patients were evaluated with contrast spiral CT of the chest and abdomen and additional imaging tests, such as nuclear magnetic resonance imaging or ultrasound, in case of symptoms or signs suggestive of distant metastasis or primary site recurrence. Resectability was based on the following criteria: primary tumor previously cured or curable, no evidence of extrapulmonary metastases, complete removal of all pulmonary metastases feasible, planned resection volume tolerable by the patient.
Among patients who underwent resection for lung metastases, 7 had received preoperative chemotherapy within 3 months of metastasectomy.
PET
Images were acquired with a General Electric Advance PET scanner (General Electric Medical Systems, Milwaukee, Wis) 1 hour after injection of approximately 370 MBq of F-18 FDG. Each patient was imaged with arms over the head, covering a field of view from neck to pelvis. A transmission scan was then performed on the thorax region to measure attenuation. Raw data were corrected for measured attenuation by segmented transmission data and then reconstructed in transaxial images by an iterative algorithm with 16 subset and order 4. Parametric standard uptake value (SUV) transaxial images were obtained as follows: SUV ϭ (pixelby-pixel activity in becquerels per cubic centimeter)/(injected dose in megabecquerls per body weight in kilograms). Circular regions of interest (ROIs) were manually drawn on transaxial images around the focal FDG-uptake area. No correction for partialvolume effect was performed. Mean value of maximum SUV of different slices of each nodule was considered for statistical analysis. Data on SUV were available for 70 of 89 PET procedures.
Surgery and Pathologic Results
Seventy lung resections were performed in 68 patients with the following pathologic results: 54 lung metastases, 7 primary lung tumors, and 9 benign lesions. Of 54 patients with lung metastasis, 41 had monolateral lung resection and 13 bilateral resection. A single lung metastasis was present in 26 patients, from 2 to 5 metastases in 21 patients, and more than 5 in 7 patients. A proper lymph node sampling was performed in 31 of 54 patients with proven lung metastasis: this included an average of 12.2 nodes and at least 1 hilar and 1 mediastinal station. In an additional 19 
patients, the mediastinal involvement was assessed by follow-up data (8 of these had 1 hilar station pathologically evaluated, average 1.5 nodes). Nodal status was not available in 4 patients.
Statistical Analysis
Comparisons of percentage of positive nodes by histologic type and sensitivity by histologic type or by nodule size category were done by the Fisher exact test. Mean SUV values were compared taking into account nodule size by regression analysis. All analyses were done with SAS software (SAS, Inc, Cary, NC).
Results
In 19 of 89 cases (21%) lung surgery was not performed on the basis of PET results, which showed extrapulmonary metastasis in 11 cases, primary site recurrence in 2, mediastinal adenopathy in 2, benign lung nodule in 4 ( Table 1) . Sites of local recurrences were colon cancer in 1 patient and sarcoma of the arm in another. Of the 11 cases of distant metastases, 5 bone lesions were confirmed by rib biopsy (2), magnetic resonance imaging (MRI) (2), or bone scan (1); 2 adrenal lesions were confirmed by CT; 1 chest wall metastasis with needle biopsy; 1 pancreatic metastasis by MRI; 1 liver and abdominal node metastases were confirmed by clinical follow-up only. Of the 2 mediastinal nodes, 1 was confirmed by mediastinoscopy and the other by progression of N2 disease at follow-up. In the 4 cases excluded from surgery, benignity was assessed by clinical follow-up, without biopsy. Among patients submitted to lung resection (70), in 2 cases clinical management was changed by PET detection of a colon cancer recurrence that was resected before lung metastasectomy and 1 liver metastases that was treated after lung surgery. In 2 further cases, distant metastases were identified by PET in the liver and pelvis, but lung metastasectomy was performed due to negative CT scan. Later follow-up confirmed the true positivity of PET staging, with tumor progression at these distant sites. There were 3 falsenegative PET extrapulmonary sites of disease: a brain meningioma, a pleural micrometastasis (diameter 1-3 mm), and a small breast cancer. A false-positive PET at distant sites occurred in 7 patients: bone hot spots in 2 patients (spine, chest wall), site of previous surgical resection in 1 patient (pelvis), neck and abdominal lymph nodes in 2 cases, and prostatic hyperplasia in 1 case. PET sensitivity, specificity, and accuracy for detection of distant deposits were 85%, 90%, and 89%, respectively.
Among patients subjected to lung metastasectomy, all cases (7/50, 14%) of mediastinal nodes involvement were detected by PET, with only 2 cases of false-positive PET at the mediastinal level. Overall sensitivity, accuracy, and negative predictive value at the mediastinal level were greater that those of CT scan (100%, 96%, and 100% vs 71%, 92%, and 95%, respectively, Table 2 ). In 2 cases of positive mediastinal PET and negative CT scan of the chest, we could have avoided exploratory thoracotomy by confirming PET results through mediastinoscopy. In the other 5 cases, preoperative detection of localized mediastinal disease by PET allowed a better approach by lung metastasectomy combined with radical mediastinal lymphadenectomy or mediastinal adjuvant radiotherapy. In 2 additional cases PET detection of major mediastinal involvement led to exclusion from surgery. At the hilar station there were 3 false-negative PET metastases (sensitivity 40%) and 5 falsenegative CT scans (sensitivity 0%) ( Table 2) . Positive lymph nodes occurred in 23% of patients with epithelial tumors (13% mediastinal) and 17% of patients with sarcoma metastases (17% mediastinal).
PET was positive at the pulmonary level in 47 of 54 (87%) patients who underwent metastasectomy. Table 3 describes sensitivity of PET in relation to lung lesions size and primary tumor type. Only 40% of nodules smaller than 10 mm were PET positive; sensitivity increased to 90% for nodules between 10 to 20 mm and 94% for nodules greater than 20 mm (P ϭ .0149). PET sensitivity was 92% for colorectal cancer, 86% for urologic neoplasms, 75% for sarcomas, and 50% for breast cancer. No significant association between sensitivity and tumor type was evident (P ϭ .5). Among the 9 patients with resected benign lesions, there were 7 false-positive PET and 2 true-negative results. In the remaining 4 patients with benign disease, lung resection was avoided based on the negative PET results. The overall sensitivity with respect to pulmonary metastases was then 87%, specificity 46%, positive predictive value 87%, negative predictive value 46%. Table 4 describes the analysis of SUV data in relation to pathologic characteristics. Mean SUV was higher in patients with colon cancer than in those with sarcoma, but no significant difference was evident between these 2 tumor types. A borderline P value was demonstrated when comparing SUV of benign and malignant lesions (.08), but it increased to .14 when adjusting SUV for nodule size. Mean SUV was lower in the 7 patients who had received preoperative chemotherapy within 3 months of lung metastasectomy (2.7 Ϯ 2.2 vs 4.5 Ϯ 3.5, P ϭ .2), but SUV reduction did not affect sensitivity, which remained 100% in this subset of patients.
Discussion
On the basis of CT scan staging, lung metastasectomy can achieve permanent cure and long-term survival in over 30% of cases. [1] [2] [3] [4] Presence of extrathoracic deposits in patients with lung metastasis is the main reason for exclusion from salvage surgery, whereas only recent reports have emphasized the importance of mediastinal staging in lung metastasis, indicating poor prognosis if nodal metastases are present. 3, 9, 10 The main result of our study was the high frequency of positive extrapulmonary PET foci. This observation has modified the treatment plan in over 20% of patients. PET detection of occult distant metastases or recurrence at the primary site avoided unnecessary lung resections or changed therapeutic strategy with prior treatment of extrathoracic disease such as combined staged liver and lung metastasectomy. Sensitivity and specificity for detection of extrapulmonary deposits in patients with lung metastases were comparable with those reported by Pieterman and colleagues 5 in potentially resectable lung cancer (85% and 90% vs 82% and 93%, respectively). PET false-negatives were limited to a brain meningioma, a small breast cancer, and a pleural metastasis. In the present study PET was not able to downstage patients by excluding equivocal evidence of distant metastasis on initial CT staging.
In this series all mediastinal node metastases were detected by PET with a sensitivity and accuracy greater than contrast CT scan. Preoperative knowledge of mediastinal node involvement may allow a better management of these patients, as it is an indication for preoperative chemotherapy and radical lymphadenectomy. On the other hand, the knowledge on hilar node metastasis may be of great importance in planning an anatomic resection, such as segmentectomy or lobectomy, instead of a simple wedge or precision resection.
In our series, mediastinal node involvement was observed in 14% of patients with resected lung metastasis, which reproduces exactly the data reported by Loehe and colleagues. 9 In addition, our study confirmed the high negative predictive value of PET in mediastinal staging, similar to that reported in lung cancer (100% present study vs 95% Pieterman and colleagues 5 .) On the other hand, given the low positive predictive value on mediastinal staging (78%), a confirmation with surgical mediastinoscopy or transbronchial biopsy is still necessary before excluding patients from surgery in the case of positive PET at the mediastinal level. Although mediastinal node metastases may have a lesser prognostic relevance in thyroid or kidney cancer, this was not the case of the 2 patients excluded from surgery in our series (sarcoma and bladder cancer). Sensitivity of PET for detection of hilar nodes was only 40%, but it was higher than CT scan. If we consider the contribution of PET scan on nodal staging, the overall change in patient management could be higher than 30% of cases.
With the increasing sensitivity of spiral CT the main limitation of radiologic assessment will become the differential diagnosis of small undetermined pulmonary nodules in patients with previous malignancy, rather than presence of occult lung metastasis. Lucas and colleagues 11 reported an 86% sensitivity rate of FDG-PET in detection of lung metastases from soft tissue tumors and a sensitivity of 100% of chest CT. Lowe and colleagues 12 reported sensitivity and specificity rates of 92% and 90%, respectively, in identifying malignant features in undetermined lung nodules in patients with or without previous malignancy. In the present study, the overall PET sensitivity on lung metastasis was 87% and the capability of a noninvasive method to differentiate benign from malignant nodules avoided biopsy in 4 cases. On the other hand, the high rate of false-positive PET caused by chronic inflammation or infection and the low specificity and negative predictive value (46%) still represent a limitation of this technique. 13 Our results, in disagreement with previous observations, 12 could be partially attributable to the absence of a cutoff value of SUV to differentiate benign from malignant nodules.
A significantly lower sensitivity was evident for nodules of less that 1 cm (40% vs 90%). PET tended to be more sensitive in the case of colon cancer lesions than in sarcomas, but the difference was not statistically significant. In agreement with prior reports, PET accuracy was similar to that of spiral CT in detection of lung nodules 11, 14 and the use of PET did not supply any additional information to alter the surgical approach (ie, bilateral vs monolateral).
Analysis of SUV in different tumor types has shown higher value of SUV in colon cancer metastasis than in sarcomas (not significant). Comparison of mean SUV value in malignant nodules and benign ones demonstrated a borderline P value, which became clearly not significant when adjusting SUV data for nodule size.
In conclusion our experience demonstrates that PET can improve the management of resectable lung metastases in a high proportion of patients. Our findings support the important role of PET in the selection of surgical candidates for lung metastasectomy with the aims of improving detection of extrathoracic disease, identifying nodal metastases, and increasing the accuracy of differential diagnosis of benign from malignant lung lesions.
